Clinical Trials Logo

Cardio-Renal Syndrome clinical trials

View clinical trials related to Cardio-Renal Syndrome.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06174623 Not yet recruiting - Heart Failure Clinical Trials

Feasibility Study to Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance

Start date: August 2024
Phase: N/A
Study type: Interventional

Evaluation of the safety and efficacy of the ModulHeart System in patients hospitalized with acute decompensated heart failure (ADHF) and diuretic resistance

NCT ID: NCT06030843 Not yet recruiting - Clinical trials for Empagliflozin in Cardiorenal Syndrome Type 1

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

TREAT-CRS
Start date: March 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.

NCT ID: NCT05368766 Not yet recruiting - Clinical trials for Cardio-Renal Syndrome

Predictive Value of Venous Excess Ultrasound Score in Management of Cardiorenal Patients

Start date: June 1, 2022
Phase:
Study type: Observational [Patient Registry]

To assess predictive value of venous excess ultrasound score in cardiorenal patient management

NCT ID: NCT05079724 Not yet recruiting - Heart Diseases Clinical Trials

Acute Kidney Injury After Cardiac Surgery

Start date: November 1, 2021
Phase:
Study type: Observational

The study aims to identify the Following: - 1. incidence and mortality of cardiac Surgery associated -AKI based on the new consensus diagnostic systems of KDIGO (Kidney Disease Improving Global Outcomes). 2. use of biomarkers for the early detection of clinical and subclinical cardiac Surgery associated-AKI. 3. risk factors and prediction models of cardiac Surgery associated-AKI. 4. optimal cardiac surgical procedures including conventional versus minimally invasive approaches, on-pump versus off-pump, and optimal management of cardiac surgical support including duration of CPB, perfusion pressure, hemodilution, and hypothermia during CPB. 5. controversial pharmacologic therapies for the prevention and treatment of cardiac Surgery associated-AKI including statins, sodium bicarbonate, and N-acetylcysteine (NAC).

NCT ID: NCT03994874 Not yet recruiting - Clinical trials for Congestive Heart Failure

Peritoneal Ultrafiltration in Cardio Renal Syndrome.

PURE
Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Randomized, controlled, unblinded, adaptive design clinical trial to evaluate the safety and efficacy of PolyCore (Polydextrin, L-Carnitine, D-xylitol) peritoneal ultrafiltration (PUF) in patients with heart failure and reduced ejection fraction (HFrEF).

NCT ID: NCT02238093 Not yet recruiting - Clinical trials for End-stage Renal Disease

Cardiorenal Syndrome in End-Stage Kidney Disease

Start date: October 2014
Phase: N/A
Study type: Observational

Cardiorenal Syndrome (CRS) is prevalent among end-stage renal disease (ESRD) patients. Recently, its prevalence is rising. There are several different clinical presentations of this syndrome. It has a high rate of morbidity and mortality. The purpose of this study is to find the connection between the heart pathology and its effect on ESRD patients. This will aid in choosing the appropriate medical therapy for these patients, and hopefully, aid in increasing their quality of life, and decrease their morbidity and mortality.

NCT ID: NCT01211886 Not yet recruiting - Clinical trials for Chronic Kidney Disease

Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)

Start date: September 2010
Phase: N/A
Study type: Observational

Admission BNP was a useful marker for diagnosing and predicting type IV cardio-renal syndrome type IV in patients with chronic kidney disease admitted to the ICU for acute heart failure in a retrospective study. Therefore, we aim to prospectively investigate the utility of serum BNP in evaluating the treatment adequacy and predicting future cardiac events in patients with type IV CRS.